Tirzepatide
Glucose-Dependent Insulinotropic Polypeptide (GIP) / GLP-1 Dual Agonist
Tirzepatide is a 39-amino-acid synthetic peptide engineered with dual agonism at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Investigated in extensive clinical trials and preclinical pharmacological assays for glucose homeostasis, lipolytic modulation, and pancreatic beta-cell insulin secretion.
Indexed for laboratory in vitro receptor binding assays and cellular synthesis research. Commercial materials are procured as non-clinical reagents under verified laboratory standards.
Chemical Structure & Metrics
Structured Chemical & Preclinical Profile
1. Chemical Identity & Sequence Architecture
Tirzepatide (Glucose-Dependent Insulinotropic Polypeptide (GIP) / GLP-1 Dual Agonist) is an analytically characterized peptide with empirical formula C225H348N48O68 (MW 4813.5 g/mol). CAS Registry: 2023788-19-2.
2. Primary Preclinical Signaling Axis
Investigated in preclinical assays for cellular signaling: Dual-receptor binding and activation across both GIP and GLP-1 G-protein coupled receptors.
3. Physical Formats & Delivery Matrices
Synthesized predominantly as high-purity lyophilized powder cakes, with secondary pre-metered pen cartridges and solution atomizers cataloged across vendors.
4. Reconstitution & Analytical Handling
Recommended reconstitution with Bacteriostatic Water (0.9% Benzyl Alcohol USP) or Sterile Diluent. Lyophilized cake stored at -20°C desiccated (stable up to 24 months). Solution stable at 2°C to 8°C refrigerated; do not freeze (stable 28 days).
Signaling Pathways & Laboratory Handling Protocols
Documented Receptor Pathways & In Vitro Signaling
Dual-receptor binding and activation across both GIP and GLP-1 G-protein coupled receptors.
Glucose-dependent potentiation of first- and second-phase insulin secretion from pancreatic beta cells.
Attenuation of postprandial glucagon secretion and delay of gastric emptying kinetics in experimental models.
Enhancement of adipocyte lipid buffering capacity via selective GIP receptor signaling cascades.
Documented in multinational Phase III SURPASS and SURMOUNT human clinical trials and in vitro receptor binding affinity assays.
Handling Parameters
Peptide Dilution & Reconstitution Calculator
Compute stock concentrations, micro-pipetting draw volumes, and U-100 syringe units with zero procedural guesswork.
Slowly introduce bacteriostatic diluent against the internal glass vial wall. Swirl gently in a circular horizontal rotation. Never shake or vortex vigorously to prevent mechanical shearing of delicate peptide bonds. Store reconstituted stock at 2°C–8°C.
Partner & Vendor Catalogues for Tirzepatide
Independent partner directory providing research-grade lyophilized vials, cartridges, atomizers, and reconstitution solvents.
Category hub featuring research-grade lyophilized vials, pens, and blends.
Full catalogue category hub with multiple mg vial sizes and blends.
Dedicated category hub listing research vials and cartridges.
UK-stocked research reagent catalogue hub featuring batch-verified peptide lots.
Global catalogue hub including international dispatch batches.
Academic Bibliography & Preclinical Studies for Tirzepatide
Primary academic indexing sourced from PubMed and peer-reviewed biotechnology journals documenting molecular mechanisms and in vitro cellular response.
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frequently Asked Chemical & Analytical Questions
Authoritative scientific clarifications regarding Tirzepatide classification, molecular pathways, and laboratory protocols.
Tirzepatide (Glucose-Dependent Insulinotropic Polypeptide (GIP) / GLP-1 Dual Agonist) is an analytically characterized peptide compound with empirical molecular formula C225H348N48O68 and molecular weight 4813.5 g/mol. It is indexed under CAS Registry Number 2023788-19-2 and categorized in research literature under Metabolic & Incretin Signaling.